The latest price target for Agile Therapeutics Inc COM PAR $0.0001 (OTC:AGRX) was reported by Maxim Group on March 18, 2024. The analyst firm set a price target for $0.00 expecting AGRX to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Agile Therapeutics Inc COM PAR $0.0001 (OTC:AGRX) was provided by Maxim Group, and Agile Therapeutics Inc COM PAR $0.0001 downgraded their hold rating.

The last upgrade for Agile Therapeutics Inc COM PAR $0.0001 happened on September 22, 2023 when Maxim Group raised their price target to $5. Maxim Group previously had a hold for Agile Therapeutics Inc COM PAR $0.0001.

The last downgrade for Agile Therapeutics Inc COM PAR $0.0001 happened on March 18, 2024 when Maxim Group changed their price target from N/A to N/A for Agile Therapeutics Inc COM PAR $0.0001.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agile Therapeutics Inc COM PAR $0.0001, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agile Therapeutics Inc COM PAR $0.0001 was filed on March 18, 2024 so you should expect the next rating to be made available sometime around March 18, 2025.

While ratings are subjective and will change, the latest Agile Therapeutics Inc COM PAR $0.0001 (AGRX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Agile Therapeutics Inc COM PAR $0.0001 (AGRX) is trading at is $1.51, which is out of the analyst’s predicted range.